Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA.
J Clin Pharm Ther. 2021 Apr;46(2):528-531. doi: 10.1111/jcpt.13317. Epub 2020 Nov 28.
Invasive fungal infections often occur in patients with comorbidities that complicate oral administration. Serum concentrations of isavuconazole were characterized after enteral tube administration.
Thirteen of 14 isavuconazole concentrations were >1 mg/dl (median 1.6 mg/dl) among those receiving enteral tube administration, which was comparable to intravenous (median 1.9 mg/dl). Higher concentrations were observed during oral administration (median 3 mg/dl).
Administration of isavuconazole via tube resulted in concentrations comparable to FDA-approved routes of administration. This route may be feasible and appropriate for select patients.
患有使口服给药复杂化的合并症的患者常发生侵袭性真菌感染。已对肠内管给药后的伊沙康唑血清浓度进行了描述。
接受肠内管给药的 14 例伊沙康唑浓度中有 13 例＞1mg/dl（中位数 1.6mg/dl），与静脉内给药（中位数 1.9mg/dl）相当。在口服给药期间观察到更高的浓度（中位数 3mg/dl）。
通过管饲给予伊沙康唑可产生与 FDA 批准的给药途径相当的浓度。这种途径对于某些特定患者可能是可行且合适的。
